Megan K Applewhite1, Benjamin C James2, Sharone P Kaplan2, Peter Angelos2, Edwin L Kaplan2, Raymon H Grogan2, Briseis Aschebrook-Kilfoy3. 1. Endocrine Surgery Research Group, Department of Surgery, The University of Chicago, 5841 S. Maryland Ave. MC 4052, Chicago, IL, 60637, USA. megan.applewhite@uchospitals.edu. 2. Endocrine Surgery Research Group, Department of Surgery, The University of Chicago, 5841 S. Maryland Ave. MC 4052, Chicago, IL, 60637, USA. 3. Division of Epidemiology, Department of Health Studies, The University of Chicago, 5841 S. Maryland Ave. MC 2007, N112, Chicago, IL, 60637, USA. brisa@uchicago.edu.
Abstract
BACKGROUND: The incidence of thyroid cancer is increasing. As such, the number of survivors is rising, and it has been shown that their quality of life (QOL) is worse than expected. Using results from the North American Thyroid Cancer Survivorship Study (NATCSS), a large-scale survivorship study, we aim to compare the QOL of thyroid cancer survivors to the QOL of survivors of other types of cancer. METHODS: The NATCSS assessed QOL overall and in four subcategories: physical, psychological, social, and spiritual well-being using the QOL-Cancer Survivor (QOL-CS) instrument. Studies that used the QOL-CS to evaluate survivors of other types of cancers were compared to the NATCSS findings using two-tailed t tests. RESULTS: We compared results from NATCSS to QOL survivorship studies in colon, glioma, breast, and gynecologic cancer. The mean overall QOL in NATCSS was 5.56 (on a scale of 0-10, where 10 is the best). Overall QOL of patients with thyroid cancer was similar to that of patients with colon cancer (mean 5.20, p = 0.13), glioma (mean 5.96, p = 0.23), and gynecologic cancer (mean 5.59, p = 0.43). It was worse than patients surveyed with breast cancer (mean 6.51, p < 0.01). CONCLUSIONS: We found the self-reported QOL of thyroid cancer survivors in our study population is overall similar to or worse than that of survivors of other types of cancer surveyed with the same instrument. This should heighten awareness of the significance of a thyroid cancer diagnosis and highlights the need for further research in how to improve care for this enlarging group of patients.
BACKGROUND: The incidence of thyroid cancer is increasing. As such, the number of survivors is rising, and it has been shown that their quality of life (QOL) is worse than expected. Using results from the North American Thyroid Cancer Survivorship Study (NATCSS), a large-scale survivorship study, we aim to compare the QOL of thyroid cancer survivors to the QOL of survivors of other types of cancer. METHODS: The NATCSS assessed QOL overall and in four subcategories: physical, psychological, social, and spiritual well-being using the QOL-Cancer Survivor (QOL-CS) instrument. Studies that used the QOL-CS to evaluate survivors of other types of cancers were compared to the NATCSS findings using two-tailed t tests. RESULTS: We compared results from NATCSS to QOL survivorship studies in colon, glioma, breast, and gynecologic cancer. The mean overall QOL in NATCSS was 5.56 (on a scale of 0-10, where 10 is the best). Overall QOL of patients with thyroid cancer was similar to that of patients with colon cancer (mean 5.20, p = 0.13), glioma (mean 5.96, p = 0.23), and gynecologic cancer (mean 5.59, p = 0.43). It was worse than patients surveyed with breast cancer (mean 6.51, p < 0.01). CONCLUSIONS: We found the self-reported QOL of thyroid cancer survivors in our study population is overall similar to or worse than that of survivors of other types of cancer surveyed with the same instrument. This should heighten awareness of the significance of a thyroid cancer diagnosis and highlights the need for further research in how to improve care for this enlarging group of patients.
Authors: Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544
Authors: Briseis Aschebrook-Kilfoy; Benjamin James; Sapna Nagar; Sharone Kaplan; Vanessa Seng; Habibul Ahsan; Peter Angelos; Edwin L Kaplan; Marlon A Guerrero; Jennifer H Kuo; James A Lee; Elliot J Mitmaker; Jacob Moalem; Daniel T Ruan; Wen T Shen; Raymon H Grogan Journal: Thyroid Date: 2015-12-01 Impact factor: 6.568
Authors: Richard Crevenna; Georg Zettinig; Mohammad Keilani; Martin Posch; Manuela Schmidinger; Christian Pirich; Martin Nuhr; Michael Wolzt; Michael Quittan; Veronika Fialka-Moser; Robert Dudczak Journal: Support Care Cancer Date: 2003-06-03 Impact factor: 3.603
Authors: Briseis Aschebrook-Kilfoy; Edwin L Kaplan; Brian C-H Chiu; Peter Angelos; Raymon H Grogan Journal: Ann Surg Oncol Date: 2013-03-17 Impact factor: 5.344
Authors: Briseis A Kilfoy; Tongzhang Zheng; Theodore R Holford; Xuesong Han; Mary H Ward; Andreas Sjodin; Yaqun Zhang; Yana Bai; Cairong Zhu; Grace L Guo; Nathaniel Rothman; Yawei Zhang Journal: Cancer Causes Control Date: 2008-11-19 Impact factor: 2.506
Authors: Ji In Lee; Soo Hyun Kim; Alice H Tan; Hee Kyung Kim; Hye Won Jang; Kyu Yeon Hur; Jae Hyeon Kim; Kwang-Won Kim; Jae Hoon Chung; Sun Wook Kim Journal: Health Qual Life Outcomes Date: 2010-09-15 Impact factor: 3.186
Authors: Eva-Maria Gamper; Lisa M Wintner; Margarida Rodrigues; Sabine Buxbaum; Bernhard Nilica; Susanne Singer; Johannes M Giesinger; Bernhard Holzner; Irene Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2015-03-13 Impact factor: 9.236
Authors: Reese W Randle; Norah M Bushman; Jason Orne; Courtney J Balentine; Elizabeth Wendt; Megan Saucke; Susan C Pitt; Cameron L Macdonald; Nadine P Connor; Rebecca S Sippel Journal: Thyroid Date: 2017-06-12 Impact factor: 6.568
Authors: Susan C Pitt; Elizabeth Wendt; Megan C Saucke; Corrine I Voils; Jason Orne; Cameron L Macdonald; Nadine P Connor; Rebecca S Sippel Journal: J Surg Res Date: 2019-07-12 Impact factor: 2.192
Authors: Maria Papaleontiou; Josh M Evron; Nazanene H Esfandiari; David Reyes-Gastelum; Kevin C Ward; Ann S Hamilton; Francis Worden; Megan R Haymart Journal: Thyroid Date: 2020-04-16 Impact factor: 6.568
Authors: Naykky Singh Ospina; Spyridoula Maraka; Ana E Espinosa De Ycaza; Hyeong Sik Ahn; M Regina Castro; John C Morris; Victor M Montori; Juan P Brito Journal: Endocrine Date: 2016-08-10 Impact factor: 3.633
Authors: Susan C Pitt; Megan C Saucke; Elizabeth M Wendt; David F Schneider; Jason Orne; Cameron L Macdonald; Nadine P Connor; Rebecca S Sippel Journal: Thyroid Date: 2020-11-04 Impact factor: 6.568